Tolmetin

Summary

Tolmetin (CHEMBL1020) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M02AA21); indicated across 3 conditions including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M02AA21 (+1 more)
• Indications: 3 conditions
• Chemistry: 257.28 Da · C15H15NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1020
Name	Tolmetin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5509
ChEBI	CHEBI:71941
ATC	M02AA21, M01AB03
Molecular formula	C15H15NO3
Molecular weight	257.28
InChIKey	UPSPUYADGBWSHF-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O

IUPAC name: 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid

ChEBI definition: A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor.

Also known as: MCN-2559, Tolmetin, Tolmetina, Tolmetine, tolmetin, TOLMETIN, TOLMETINE, TOLMETIN SODIUM

Parent form; salt/anhydrous children: CHEMBL1200613, CHEMBL1437585, CHEMBL1556918

Patent coverage: 14,643 distinct patent families (60,332 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 60,331 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Aldo-keto reductase family 1 member B1, Interleukin-8, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Lactoylglutathione lyase, Aldo-keto reductase family 1 member B1.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	7.39	IC50	41	nM	CHEMBL_ACT_7812952
PTGS1	7.38	AC50	41.5	nM	CHEMBL_ACT_25206588
PTGS1	7.09	AC50	81	nM	CHEMBL_ACT_25205658
CXCL8	7.05	IC50	90	nM	CHEMBL_ACT_2695392
PTGS1	6.46	IC50	350	nM	CHEMBL_ACT_25650355
PTGS2	6.09	IC50	820	nM	CHEMBL_ACT_25650356
P07943	5.67	IC50	2153	nM	CHEMBL_ACT_7810899
AKR1B1	5.62	IC50	2390	nM	CHEMBL_ACT_12595748

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).